These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 6871919)

  • 1. Cardiac effects of aprindine in patients with or without cardiac dysfunction: echocardiographic and clinical evaluation.
    Shimada R; Araki H; Orita Y; Nakagaki O; Nakamura M
    Clin Ther; 1983; 5(4):348-56. PubMed ID: 6871919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term oral antiarrhythmic therapy with aprindine: effects on cardiac function and adverse effects.
    Tsutsui H; Araki H; Nagata Y; Nakamura M
    Clin Ther; 1984; 6(6):770-7. PubMed ID: 6509460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of clinical efficacy and plasma levels of aprindine.
    Malini PL; Ambrosioni E; Bracchetti D; Magnani B
    Int J Clin Pharmacol Biopharm; 1979 Oct; 17(10):396-403. PubMed ID: 500254
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular effects of aprindine, a new antiarrhythmic drug.
    Remme WJ; Verdouw PD
    Eur J Cardiol; 1975 Dec; 3(4):307-13. PubMed ID: 1193115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effects of intravenous aprindine on hemodynamics in patients with cardiac dysfunction and its pharmacodynamics in patients with premature ventricular contractions].
    Matsumoto N; Hayasaki K
    Kokyu To Junkan; 1990 Apr; 38(4):383-9. PubMed ID: 1694595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of aprindine and disopyramide on reperfusion-induced arrhythmias and cardiac function in isolated rat hearts.
    Iwasaki S; Araki H; Yamakawa T; Nishi K; Miyauchi Y
    Arch Int Pharmacodyn Ther; 1989; 300():174-85. PubMed ID: 2619422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical effects and plasma concentration levels of aprindine hydrochloride in patients with tachyarrhythmias].
    Kasahara S; Shibata N; Mizobe H; Shoda M; Miyazaki Y; Miura M; Miyazawa Y; Komatsu Y
    Kokyu To Junkan; 1989 Nov; 37(11):1225-30. PubMed ID: 2602679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effective plasma concentrations of aprindine in canine ventricular arrhythmias.
    Hashimoto K; Komori S; Ishii M; Kamiya J
    J Cardiovasc Pharmacol; 1984; 6(1):12-9. PubMed ID: 6199593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aprindine for treatment of ventricular arrhythmias in the dog.
    Muir WW; Bonagura JD
    Am J Vet Res; 1982 Oct; 43(10):1815-9. PubMed ID: 7149383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effect of aprindine in patients with normal and pre-damaged impulse forming and excitation conducting system. Second communication: Conduction times (author's transl)].
    Pantlen H; Runge M; Luckmann E
    Arzneimittelforschung; 1980; 30(2):324-8. PubMed ID: 7378113
    [No Abstract]   [Full Text] [Related]  

  • 11. Antiarrhythmic and antifibrillatory properties of aprindine.
    Kroll DA; Lucchesi BR
    J Pharmacol Exp Ther; 1975 Aug; 194(2):427-34. PubMed ID: 1151768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term follow-up of patients receiving aprindine. Safety and efficacy.
    Strasberg B; Prechel D; Bauman J; Coelho A; Swiryn S; Bauernfeind R; Rosen KM
    Arch Intern Med; 1983 Nov; 143(11):2131-3. PubMed ID: 6639232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Detection of aprindine and its metabolites in plasma and urine].
    Wirth KE; Breithardt G; Michaelis L
    Herz; 1983 Oct; 8(5):302-8. PubMed ID: 6642401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-dose dobutamine responsiveness in idiopathic dilated cardiomyopathy: relation to exercise capacity and clinical outcome.
    Scrutinio D; Napoli V; Passantino A; Ricci A; Lagioia R; Rizzon P
    Eur Heart J; 2000 Jun; 21(11):927-34. PubMed ID: 10806017
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Changes in hemodynamics and contractility during supraventricular tachycardias and after electrical or aprindin-induced termination (author's transl)].
    Weppner HG; Merle H; Schlepper M
    Arzneimittelforschung; 1976; 26(12):2205-8. PubMed ID: 1037277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effects of aprindine on the electromechanical coupling of the myocardium and smooth muscle].
    Cargnelli G; Finotti P; Gobbato S; Padrini R
    Boll Soc Ital Biol Sper; 1980 Mar; 56(5):474-80. PubMed ID: 7387791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical efficacy and plasma levels of oral aprindine, a new antiarrhythmic drug].
    Kikuchi H; Honda T; Kugimiya H; Matuda H; Matunaga T; Takemiya S; Hayasaki K
    Kokyu To Junkan; 1985 Mar; 33(3):433-40. PubMed ID: 4012073
    [No Abstract]   [Full Text] [Related]  

  • 18. The influence of growth hormone (GH) therapy on cardiac performance in patients with childhood onset GH deficiency.
    Minczykowski A; Gryczynska M; Ziemnicka K; Czepczynski R; Sowinski J; Wysocki H
    Growth Horm IGF Res; 2005 Apr; 15(2):156-64. PubMed ID: 15809020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects on rabbit cardiac potentials of aprindine and indecainide, a new antiarrhythmic agent, in normoxia and hypoxia.
    Dennis PD; Vaughan Williams EM
    Br J Pharmacol; 1985 May; 85(1):11-9. PubMed ID: 4027460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effect of aprindine in patients with normal and pre-damaged impulse forming and excitation conducting system/First communication; Sinus node function (author's transl)].
    Pantlen H; Runge M; Luckmann E
    Arzneimittelforschung; 1980; 30(1):92-5. PubMed ID: 7370079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.